4.7 Article

Microfluidic Approach to Cocrystal Screening of Pharmaceutical Parent Compounds

期刊

CRYSTAL GROWTH & DESIGN
卷 12, 期 12, 页码 6023-6034

出版社

AMER CHEMICAL SOC
DOI: 10.1021/cg3011212

关键词

-

资金

  1. Abbott Laboratories
  2. U.S. Department of Energy [DE-FG02-07ER46453, DE-FG02-07ER46471]

向作者/读者索取更多资源

We describe a microfluidic approach to screen for the formation of cocrystalline solid forms of pharmaceutical parent compounds (PCs). Saturated solutions of PCs and of cocrystal formers dissolved in a variety of solvents are precisely metered in arrays of 48 wells to enable the combinatorial mixing of all possible combinations. Key characteristics of the microfluidic approach, including small quantities (similar to 240 mu g/48 conditions), the ability to generate and screen 48 unique conditions per chip, and the ability to identify solid forms on-chip via Raman spectroscopy, enable solid form screening very early in the drug development process. In contrast, current approaches require on the order of similar to 240 mg for 48 conditions, thus delaying solid form screening to later stages of the drug development. Sequential screening experiments using caffeine as the model compound were conducted to validate the on-chip approach reported here. Preliminary screens were executed to identify conditions with the highest propensity for crystallization and to identify the cocrystal formers (CCFs) resulting in formation of cocrystals via on-chip Raman spectroscopy. Next, the identified, promising conditions were replicated to confirm reproducibility and consistency of the on-chip outcomes. Nine cocrystals of caffeine were identified in this way.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据